Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Lifestyle interventions effective against nonobese NAFLD patients

06 Dec 2018

Lifestyle interventions appear to effectively induce remission of nonalcoholic fatty liver disease (NAFLD) in both obese and nonobese patients, reports a new study.

The study included 154 NAFLD patients who were randomly assigned to receive usual care (n=77) or a 12-month lifestyle intervention programme and regular exercise (n=77). In each group, 39 and 38 patients had body mass index (BMI) <25 and 25 kg/m2, respectively. Proton-magnetic resonance spectroscopy was used to assess the primary outcome of NAFLD remission.

Significantly more patients with BMI <25 kg/m2 who received the intervention vs usual care had NAFLD remission at 12 months (67 percent vs 18 percent; p<0.001). In the respective groups, the mean decline in intrahepatic triglyceride content (IHTG) was 6.1 percent and 1.3 percent, the difference between which was statistically significant (p=0.001).

In patients with BMI 25 kg/m2, 61 percent of those who received the lifestyle intervention programme achieved NAFLD remission. This effect was significantly greater than that from usual care (21 percent; p<0.001). The resulting mean reductions in IHTG were 7.4 percent and 2.9 percent, respectively (p=0.004).

The effects of lifestyle intervention also appeared sustainable. A the 6-year follow-up, significantly more participants who received the exercise intervention vs controls had BMI lower than baseline (19.1 percent vs 8.6 percent; p=0.037).

Moreover, although rebound in body weight was observed after termination of the intervention, the mean change in body weight at year 6 was significantly more pronounced in the intervention vs control group (–1.9±4.7 vs 0.4±3.3 kg; p=0.0022).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.